This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Soroka University Medical Center.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Soroka University Medical Center
ClinicalTrials.gov Identifier:
NCT00299910
First received: March 6, 2006
Last updated: May 20, 2008
Last verified: May 2008
  Purpose
This study will assess in a double blind placebo controlled fashion the effects of a 12 week course of oral montelukast/placebo on polysomnographic and radiological findings and will characterize the systemic (serum,urine) and local (upper airway collected biological samples) inflammatory response in children (2-10 years of age) with sleep disordered breathing, fittingthe inclusion and exclusion criteria.

Condition Intervention Phase
Sleep Disordered Breathing Drug: Montelukast Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing

Resource links provided by NLM:


Further study details as provided by Soroka University Medical Center:

Estimated Enrollment: 50
Study Start Date: March 2005
  Eligibility

Ages Eligible for Study:   2 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:2-10 years old

1<AHI<8 measured in an overnight PSG

Exclusion Criteria:

Asthma Previous use or allergy to montelukast Use of antibiotics in the previous 3 weeks Use of corticosteroids in the previous 3 months Craniofacial dysmorphism Genetic or metabolic defined illnesses Adenotonsillectomy or adenoidectomy in the past

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00299910

Contacts
Contact: Aviv D Goldbart, MD, MSc 972-8-6403400 avivgold@bgu.ac.il

Locations
Israel
Pediatric Sleep Center, Soroka University Medical Center Recruiting
Beer-Sheva, Israel
Contact: Aviv D Goldbart, MD, MSc    972-8-6403400    avivgold@bgu.ac.il   
Sponsors and Collaborators
Soroka University Medical Center
Investigators
Principal Investigator: Asher Tal, MD Soroka University Medical Center
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00299910     History of Changes
Other Study ID Numbers: sor388505ctil
Study First Received: March 6, 2006
Last Updated: May 20, 2008

Additional relevant MeSH terms:
Respiratory Aspiration
Respiration Disorders
Respiratory Tract Diseases
Pathologic Processes
Montelukast
Anti-Inflammatory Agents
Anti-Asthmatic Agents
Respiratory System Agents
Leukotriene Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP1A2 Inducers
Cytochrome P-450 Enzyme Inducers
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 26, 2017